GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » EPS (Diluted)
Switch to:

Incyte (NAS:INCY) EPS (Diluted)

: $1.52 (TTM As of Dec. 2022)
View and export this data going back to 1993. Start your Free Trial

Incyte's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $1.52.

Incyte's EPS (Basic) for the three months ended in Dec. 2022 was $0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $1.54.

Incyte's EPS without NRI for the three months ended in Dec. 2022 was $0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $1.52.

During the past 12 months, Incyte's average EPS without NRIGrowth Rate was -64.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Incyte's highest 3-Year average EPS without NRI Growth Rate was 157.10% per year. The lowest was -74.10% per year. And the median was 9.20% per year.


Incyte EPS (Diluted) Historical Data

The historical data trend for Incyte's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 2.05 -1.36 4.27 1.52

Incyte Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 0.17 0.72 0.50 0.13

Competitive Comparison

For the Biotechnology subindustry, Incyte's EPS (Diluted), along with its competitors' market caps and EPS (Diluted) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte EPS (Diluted) Distribution

For the Biotechnology industry and Healthcare sector, Incyte's EPS (Diluted) distribution charts can be found below:

* The bar in red indicates where Incyte's EPS (Diluted) falls in comparison to its industry or sector. The grey bar indicates the EPS (Diluted)'s extreme value range as defined by GuruFocus.



Incyte EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Incyte's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(340.66-0)/223.958
=1.52

Incyte's Diluted EPS for the quarter that ended in Dec. 2022 is calculated as

Diluted EPS (Q: Dec. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(28.461-0)/224.954
=0.13

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte  (NAS:INCY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Incyte EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Incyte's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (NAS:INCY) Business Description

Incyte logo
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Susanne Schaffert director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Thomas Tray officer: Principal Accounting Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Edmund Harrigan director
Michael James Morrissey officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Jonathan Elliott Dickinson officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Christiana Stamoulis officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Maria E Pasquale officer: EVP & General Counsel C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Vijay K Iyengar officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Steven H Stein officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul Trower officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142

Incyte (NAS:INCY) Headlines